S100A12 and leprosy: Recently, a multi-biomarker test (MBT) evaluating αPGL-I IgM, IP-10, CRP, S100A12, and ApoA1 was successfully used to discriminate patients with MB and PB leprosy from control individuals in high and low leprosy endemic areas.13